Literature DB >> 18633224

[Involvement of zinc in taste disturbance occurring during treatment for malignant tumor in the chest and the effects of polaprezinc oral disintegrating tablets (a retrospective study)].

Yoko Nakata1, Tomonori Hirashima, Yoko Kondou, Yoshie Tokuoka, Hitomi Imazato, Kaori Iwata, Yukari Oomori, Akihiro Yamato, Saburou Shimizu, Sadako Nagao, Kaoru Matsui, Noriko Abe.   

Abstract

We analyzed the correlation between serum zinc levels and taste disturbance, and between patient backgrounds and serum zinc levels or taste disturbance, and evaluated the effects of polaprezinc oral disintegrating tablets on taste disturbance in 29 patients with lung cancer and one patient with malignant pleural mesothelioma who were receiving chemotherapy. Taste disturbance developed in 11 (36.7%) out of 30 patients. Serum zinc levels significantly correlated with taste disturbance (p=0.0227). Serum zinc levels were significantly lower (p=0.0235) and taste disturbance tended to be more frequent (p=0.0625) in males. Polaprezinc improved taste disturbance in 5 of 8 patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633224

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy.

Authors:  Karla Sánchez-Lara; Ricardo Sosa-Sánchez; Dan Green-Renner; Cindy Rodríguez; Alessandro Laviano; Daniel Motola-Kuba; Oscar Arrieta
Journal:  Nutr J       Date:  2010-03-24       Impact factor: 3.271

2.  Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.

Authors:  Ken Ito; Satoshi Yuki; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Kazuaki Harada; Shintaro Nakano; Rika Saito; Takayuki Ando; Kentaro Sawada; Masataka Yagisawa; Atsushi Ishiguro; Masayoshi Dazai; Ichiro Iwanaga; Kazuteru Hatanaka; Atsushi Sato; Ryusuke Matsumoto; Yoshiaki Shindo; Miki Tateyama; Tetsuhito Muranaka; Masaki Katagiri; Isao Yokota; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
Journal:  Support Care Cancer       Date:  2022-03-15       Impact factor: 3.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.